Menu

Top Stories

Published on Tuesday, February 26, 2019

The Alpha-1 Foundation gears up for the 2019 Global meetings in Dubrovnik, Croatia

The Alpha-1 Foundation gears up for the 2019 Global meetings in Dubrovnik, Croatia

MIAMI, Feb. 26th, 2019 - The 7th Alpha-1 Global Patient Congress and 4th International Research Conference on Alpha-1 Antitrypsin will be held April 3-6, at the Sheraton Dubrovnik Riviera Hotel in Dubrovnik, Croatia. Patient leaders, physicians and scientists from around the world will come together to discuss the latest developments in patient advocacy, clinical care and Alpha-1 Antitrypsin Deficiency (Alpha-1) research. 

With a rich history of international collaboration, the Foundation is committed to Alphas worldwide and is proud to host representatives from 32 countries. Through the dedication of the Conference Planning Committee, we are looking forward to another outstanding event. The commitment to the mission drives the Alpha-1 Global program each day, to increase awareness, detection, and access to care for Alphas around the world.  

“The recent changes in the Alpha-1 Global program offers me the opportunity to reshape our outreach to the entire Alpha-1 community, globally. Our strategic alliances are strong and will be reaffirmed in Dubrovnik, Croatia, at our International Scientific Conference and concurrent International Patient Congress. I would like to extend my gratitude to the Internal Conference Planning Committee, Richard Lovrich, who will be our emcee, and the Foundation’s hardworking staff and volunteers,” expressed Miriam O’Day, president and CEO of the Alpha-1 Foundation.

“These events will be the first international meetings I have attended since our meeting in Barcelona, in 2013. This is an exciting opportunity to be able to collaborate and strategize about the future of the Global program in my new role as president and CEO,” she added.

The 2019 meeting will begin with the 4th International Research Conference on Wednesday and Thursday, April 3-4. The Research Conference theme titled “Beyond Folding: Disease Progression and Therapeutic Options” is chaired by Professor Rob Stockley from University Hospitals Birmingham, United Kingdom. 

The program agenda for the 4th International Research Conference is available to view here

We will continue with representatives from 32 countries at the Global Patient Congress with a welcome reception and networking dinner where Alpha-1 patients, physicians and researchers can interact on Thursday, April 4th. The patient congress will continue Friday and Saturday, April 5-6.

The program agenda for the 7th Alpha-1 Global Patient Congress is available to view here

A special thank you to our outstanding Global Conference Planning Committee and Global Advisory Committee:

  • Cristina Barbiero, National Association Alfa-1 AT Italy, EU Advocacy Working Group, Italy
  • Jim Clarke, Alpha-1 Association New Zealand Co-Leader Alpha-1 Support Group, New Zealand
  • Shane Fitch, Lovexair Foundation - President, Spain
  • Elena Goyanes, Alpha-1 Association Spain, EU Advocacy Working Group, Spain
  • Karen O'Hara, Alpha-1 UK Support Group - ERN - Lung, EARCO, UK
  • Carlos Cambon, Alpha-1 Association Argentina, Argentina  
  • Martina Cambon, Alpha-1 Association Argentina, Argentina
  • Frank Willersinn, MD, Alpha-1 Plus, Belgium
  • Marion Bouchecareilh, University of Bordeaux, Alpha-1 Liver Research, France
  • Robert Durlik, Alpha-1 Poland, Founder, Poland
  • Robert Kroesen, Patient Representative, Panama
  • Tim Frost, AlphaNet Board Member, USA

Global Advisory Committee: 

  • Jeanine D’Armiento, MD, PhD, Alpha-1 Foundation – Chair, USA
  • Robert Sandhaus, MD, PhD, FCCP, Alpha-1 Foundation Medical Director, USA
  • Robert Stockley, MD, Director Lung Immuno Biochemical Research Laboratory, UK
  • Adam Wanner, MD, Alpha-1 Foundation Scientific Director, USA

The Alpha-1 Foundation graciously thanks the 2019 Alpha-1 Global Patient Congress and Research Conference Sponsors. Presenting Sponsors: AlphaNet, CSL Behring and Grifols. Gold Sponsors: Arrowhead, Kamada and Vertex. Bronze Sponsors: Dicerna and Mereo BioPharma.

CLICK HERE TO REGISTER TODAY

For additional information on the upcoming events, please contact Randel Plant, global programs manager, rplant@alpha1.org or 877-228-7321 ext. 306.

For hotel and travel arrangements, please contact Adriana De Arce, manager of scientific events, adearce@alpha1.org or 877-228-7321 ext. 269.


Print

White House prepares to ban flavored e-cigs

Tuesday, September 17, 2019
The Trump administration said it is planning to ban all e-cigarette flavors following a recent nationwide outbreak of severe lung illnesses linked to vaping and five reported deaths, according to pool reports. President Donald Trump told...
Divider

Breaking a 10-year streak, the number of uninsured Americans rises

Friday, September 13, 2019
For the first time in a decade, the number of Americans without health insurance has risen — by about 2 million people in 2018 — according to the annual U.S. Census Bureau report. The Census found that 8.5% of the U.S. population...
Divider

House Speaker Nancy Pelosi to release drug pricing plan after Congress returns

Thursday, September 12, 2019
As published on the National Health Council Insider and other news outlets, House Speaker Nancy Pelosi will release a drug-pricing plan shortly after Congress returns to work after its August recess, a House Democratic aide confirmed. Democrats...
Divider

Study analyzes the degree of concordance among international guidelines regarding Alpha-1 Antitrypsin Deficiency

Thursday, September 12, 2019
The International Journal of Chronic Obstructive Pulmonary Disease recently published the outcomes of a study entitled “An analysis of the degree of concordance among international guidelines regarding alpha-1 antitrypsin deficiency,”...
Divider

The biological effects of double-dose alpha-1 antitrypsin augmentation therapy: A pilot clinical trial

Thursday, September 12, 2019
The American Journal of Respiratory and Critical Care Medicine, of the American Thoracic Society (ATS), recently published an article about the outcomes of a clinical trial entitled: “Effect of Double Dose of Alpha 1-antitrypsin Augmentation...
Divider

News and updates from the U.S. COPD Coalition

Wednesday, September 11, 2019
The U.S. COPD Coalition (USCC), which the Alpha-1 Foundation is a member of, has remained engaged in issues confronting our communities and continued its collaboration with other groups to positively impact access to diagnosis, treatment, and...
Divider

FDA and NIH public workshop: Agenda now available

Wednesday, September 4, 2019
The U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) are sponsoring the workshop entitled “Developing Therapeutics for Alpha-1 Antitrypsin Deficiency,” at the Natcher Conference Center, Building 45...
Divider

Update: CSL Behring announcement on their product Zemaira

Monday, August 19, 2019
The Alpha-1 Foundation received the following communication update from CSL Behring, regarding Zemaira®, their prescription drug for augmentation therapy for the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1): "CSL Behring is...
Divider

DNA data shared in ways patients may find surprising

Tuesday, August 13, 2019
Deals between drugmakers and hospital systems to mine the genetic profiles of hospital patients are triggering concerns over the control of valuable genetic data. Drugmakers have been spending hundreds of millions of dollars for access to...
Divider

Arrowhead Pharmaceuticals doses first patient in SEQUOIA Phase 2/3 Study of ARO-AAT for treatment of Alpha-1 liver disease

Thursday, August 8, 2019
Arrowhead Pharmaceuticals Inc. announced that it has dosed the first patient in SEQUOIA (AROAAT2001), a potentially pivotal Phase 2/3 clinical study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference...
Divider

CSL Behring announcement on their product Zemaira

Tuesday, August 6, 2019
Today, the Alpha-1 Foundation received the following communication from CSL Behring, regarding Zemaira®, their prescription drug for augmentation therapy for the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1). “CSL Behring...
Divider

The 28th Annual Alpha-1 National Conference: The Alpha of Tomorrow

Tuesday, July 23, 2019
Orlando, Florida was the site of the largest gathering of Alphas, caregivers, family members, researchers, industry representatives, and the Alpha-1 community in the world, as the Alpha-1 Foundation held its 28th Annual Alpha-1 National...
Divider
12345678910Last

Article Search

Enter keywords in text box and click Search button for results.

Archive